Ambrilia To Announce U.S. Octreotide Partner By Year-End
This article was originally published in The Pink Sheet Daily
Executive Summary
The Canadian company will pair with Teva in Europe on its formulation of Novartis’ acromegaly therapy Sandostatin LAR.
You may also be interested in...
Merck Gains Early-Stage Protease Inhibitor For HIV/AIDS Through Ambrilia Deal
Licensing agreement includes rights to Ambrilia's lead compound PPL-100 in Phase I development as a once-daily, first-line oral therapy for HIV.
Forest Files Memantine/Donepezil Fixed Combination For Alzheimer’s
Commercialization of the fixed-dose combo buys lifecycle management for Forest and should support future drug development for partner Adamas, the originator of the technology behind the combination.
Alzheimer’s, BRAIN Initiative Highlighted In $30 Billion NIH Budget Proposal
President Obama’s proposed $56 billion Opportunity, Growth and Security Initiative would add nearly $1 billion to the NIH budget but it is funded by offsets that are likely nonstarters in Congress.